| 1 |
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Clin Liver Dis (Hoboken), 2018, 20, 11(4)：81.
|
| 2 |
Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1991.
|
| 3 |
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1)：73-84.
|
| 4 |
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.
|
| 5 |
Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J]. Hepatol Int, 2020，14(2)：259-269.
|
| 6 |
Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary[J]. J Gastroenterol Hepatol, 2007, 22(6): 775-777.
|
| 7 |
Kwon CHD, Joh JW, Lee KW, et al. Safety of donors with fatty liver in liver transplantation[J]. Transplant Proc, 2006, 38(7): 2106-2107.
|
| 8 |
Nikeghbalian S, Nejatollahi SMR, Salahi H, et al. Does donor′s fatty liver change impact on early mortality and outcome of liver transplantation[J]. Transplant Proc, 2007, 39(4): 1181-1183.
|
| 9 |
Trotter JF. Thin chance for fat people (to become living donors)[J]. Liver Transpl, 2001, 7(5): 415-417.
|
| 10 |
Brandhagen D, Fidler J, Rosen C. Evaluation of the donor liver for living donor liver transplantation[J]. Liver Transpl, 2003, 9(10 Suppl 2): S16-S28.
|
| 11 |
Kim H, Lee K, Lee KW, et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation[J]. Clin Transplant, 2014, 28(5): 521-529.
|
| 12 |
Kim H, Lee KW, Lee K, et al. Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients[J]. Hepatol Res, 2018, 48(3): E162-E171.
|
| 13 |
Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation[J]. Transplantation, 2019, 103(1): e14-e21.
|
| 14 |
Vallin M, Guillaud O, Boillot O, et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis[J]. Liver Transpl, 2014, 20(9)：1064-1071.
|
| 15 |
Germani G, Laryea M, Rubbia-Brandt L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation[J]. Transplantation, 2019, 103(1): 57-67.
|
| 16 |
Narayanan P, Mara K, Dierkhising R, et al. 425 underlying NASH and recurrent or de novo allograft steatosis are predictive of long term cardiovascular events in liver transplant recipients[J]. Gastroenterology, 2016, 150(4): S1033.
|
| 17 |
Hanouneh IA, Macaron C, Lopez R, et al. Recurrence of disease following liver transplantation: nonalcoholic steatohepatitis vs hepatitis C virus infection[J]. Int J Organ Transplant Med, 2011, 2(2): 57-65.
|
| 18 |
Alten TA, Negm AA, Voigtländer T, et al. Safety and performance of liver biopsies in liver transplant recipients[J]. Clin Transplant, 2014, 28(5): 585-589.
|
| 19 |
van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy[J]. Radiology, 2010, 256(1): 159-168.
|
| 20 |
Hepburn MJ, Vos JA, Fillman EP, et al. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study[J]. BMC gastroenterology, 2005, 5: 14.
|
| 21 |
Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis[J]. PLoS One, 2017, 12(9): e0185192.
|
| 22 |
Pfitzmann R, Nüssler NC, Hippler-Benscheidt M, et al. Long-term results after liver transplantation[J]. Transpl Int, 2008, 21(3): 234-246.
|
| 23 |
Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events[J]. Liver Transpl, 2007, 13(8): 1109-1114.
|
| 24 |
Bianchi G, Marchesini G, Marzocchi R, et al. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression[J]. Liver Transpl, 2008, 14(11)：1648-1654.
|
| 25 |
Miller LW. Cardiovascular toxicities of immunosuppressive agents[J]. Am J Transplant, 2002, 2(9): 807-818.
|
| 26 |
Charlton M, Rinella M, Patel D, et al. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: Results of a randomized multicenter study[J]. Transplantation, 2017, 101(12): 2873-2882.
|
| 27 |
Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of " seed and soil" [J]. Am J Gastroenterol, 2010, 105(3): 613-620.
|
| 28 |
Hübscher SG. What is the long-term outcome of the liver allograft？[J]. J Hepatol, 2011, 55(3): 702-717.
|
| 29 |
Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis[J]. Clin Gastroenterol Hepatol, 2013, 11(12): 1667-1672.
|
| 30 |
Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C[J]. Hepatol Res, 2018, 48(3): E335-E339.
|
| 31 |
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2014, 46(4): 352-356.
|
| 32 |
Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis[J]. Hepatology, 2015, 62(6): 1742-1756.
|
| 33 |
Textor SC, Taler SJ, Canzanello VJ, et al. Posttransplantation hypertension related to calcineurin inhibitors[J]. Liver Transpl, 2000, 6(5)：521-530.
|
| 34 |
Mohameda O, Jamesp W. FDA adverse event reports on statin-associated rhabdomyolysis[J]. Ann Pharmacother, 2002, 36(2): 288-295.
|